Clinical Trial Risk Tool featured in Clinical Leader

Published · Updated · Thomas Wood
Clinical Trial Risk Tool featured in Clinical Leader

The Clinical Trial Risk Tool has been featured in a guest column by Thomas Wood, director of Fast Data Science, in Clinical Leader, titled A Tool To Tackle The Risk Of Uninformative Trials, in cooperation with Abby Proch, Executive Editor at Clinical Leader.

In this article, Thomas Wood discusses the issue of uninformative clinical trials in pharmaceutical research. Uninformative trials fail to provide meaningful results, either because they don’t address key questions or are poorly designed. These trials waste resources, expose participants to unnecessary risks, and hinder progress in medical knowledge.

Wood uses the definition of “uninformative trials” from Zarin et al (2019)[1] as trials that do not deliver informative results, even though the investigated treatment may be effective or ineffective. An informative trial, according to experts, must meet five conditions: addressing an important question, providing meaningful evidence, being feasible, conducted scientifically, and reporting methods and results promptly.

The Clinical Trial Risk Tool was created to prevent such trials by providing features like a clinical trial budget estimator based on real-world cost data. The development of the first version of the tool was published in Gates Open Research[2]. In future, the tool could retrieve past trials with similar endpoints or inclusion/exclusion criteria to improve protocol design. It could also generate personalised feedback for different stakeholders, such as medical professionals, financial planners, and patient advocates.

Fast Data Science’s Clinical Trial Risk Tool offers a solution by allowing users to upload trial protocols, where AI analyzes the document for risk and cost factors. The tool estimates trial costs and identifies risks, helping to avoid uninformative outcomes early in the design process.

References

  1. Zarin, Deborah A., Steven N. Goodman, and Jonathan Kimmelman. “Harms from uninformative clinical trials.” Jama 322.9 (2019): 813-814, https://pubmed.ncbi.nlm.nih.gov/31343666/
  2. Wood, Thomas A., and Douglas McNair. “Clinical Trial Risk Tool: software application using natural language processing to identify the risk of trial uninformativeness.” Gates Open Research 7.56 (2023): 56. https://gatesopenresearch.org/articles/7-56/v1
  3. Wood, Thomas A., A Tool To Tackle The Risk Of Uninformative Trials, Clinical Leader, 2025.

Elevate Your Team with NLP Specialists

Unleash the potential of your NLP projects with the right talent. Post your job with us and attract candidates who are as passionate about natural language processing.

Hire NLP Experts

AI Consulting
Data science consulting

AI Consulting

Unlock your business potential with expert AI consulting services from Fast Data Science. Discover strategies to accelerate growth and outperform competitors.

AI for financial advice
Generative ai

AI for financial advice

Financial advisors, like lawyers, are regulated in the UK. All financial advisors should be registered with the Financial Conduct Authority (FCA) and must have certain qualifications and have signed up to a code of ethics. UK financial advisors must also complete professional training every year.

How good are the best large language models in 2026?
Generative aiLegal ai

How good are the best large language models in 2026?

Which is the best AI for legal questions in 2026? We tested 16 Large Language Models (AIs) from the last two years on a law exam.

What we can do for you

Transform Unstructured Data into Actionable Insights

Contact us